Insider trade

CEO sold ~$135K of UTHR shares in the open market

Traded Sep 23, 2026 · Filed Sep 25, 2026

~$135K
Approx. value · 270 sh @ $498.38: 325K
Holds after · shares reported: +10.7%
stock since the trade · S&P 500 +1.5%, $489.42 → $541.62 on Oct 6

Why it stands out

The CEO of United Therapeutics sold $135K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 23, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 25, 2026

CEOIndirect holding$100K–$500KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$134,563

Shares × reported transaction price

Timing vs results

49 days after results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $489.42 on Sep 23, 2026, 18% above its 52-week low and 18% below its high, after a 5% drop over the previous 30 trading days

52-week range $415.34 (Oct 28, 2025) to $596.76 (May 6, 2026), 41% of the way up, from 243 adjusted closes. 30 trading days earlier: $515.50 on Aug 11, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001106578-26-000148
Filed / recorded: Sep 25, 2026, 12:31 AM UTC
Added to OQRO: Oct 6, 2026, 9:34 PM UTC
Parser: form4-xml-v2
Data quality: Verified: identifiers matched exactly
Issuer: UNITED THERAPEUTICS Corp
Issuer CIK: 1082554
Ticker: UTHR
Reporting person: Martine A Rothblatt
Relationship: Director, Officer
Officer title: Chairperson & CEO
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Sep 23, 2026
Transaction code: S
Shares / units: 270
Price per share: $498.38
Acquired / disposed: Disposed (D)
Shares owned after: 324,773
Ownership form: Indirect — by Trust
Amendment: No

Footnotes from the filing

This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
This transaction was executed in multiple trades at prices ranging from $497.80 to $498.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

Around the same time

Martine A RothblattChairperson & CEO

Filed yesterday

9,500Shares · @ $117.76

Traded Oct 5 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record

Martine A Rothblatt (Chairperson & CEO) sold ~$269K of United Therapeutics

Scheduled in advanceFiled yesterday

Martine A Rothblatt (Chairperson & CEO) sold ~$486K of United Therapeutics

Scheduled in advanceFiled yesterday